Robert Wesolowski
Dr Robert Wesolowski, MD is an expert in Oncology at James Cancer Hospital (United States). As of October 2026, ScienceLeadR ranks Robert Wesolowski in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Robert Wesolowski has authored 291 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 4 of them ongoing. SLR score: 1,254 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Neurology - Pharmacy - Endocrinology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 291
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Self-reported sleep disturbances during chemotherapy mediate circulating IL-1β effects on subjective cognitive decline in breast cancer patients. PMID 42933582 — neurobehavioral manifestations, breast neoplasms, sleep, neoplasms, cognitive dysfunction, drug therapy, aftercare, signs and symptoms, breast, therapeutics, cognition, chemotherapy | Brain Behav Immun | 2026 | 0 |
| The gut microbiome in chemotherapy-induced fatigue: Exploring clinical associations and modulation via fecal microbiota transplantation in female mice. PMID 42633730 — fecal microbiota transplantation, paclitaxel, brain, drug therapy, fluorouracil, fatigue, therapeutics, diarrhea, gastrointestinal microbiome, transplantation, microbiota, chemotherapy | Int Immunopharmacol | 2026 | 0 |
| Effect of tango versus exercise on chemotherapy-induced neuropathy after breast cancer treatment: a Phase II randomized controlled trial. PMID 42620214 — exercise, breast neoplasms, neoplasms, drug therapy, signs and symptoms, breast, therapeutics, retention, psychology, chemotherapy | Res Sq | 2026 | 0 |
| Primed to feel, not to flare: Early life adversity and psychological sensitivity to interleukin-6 in a randomized trial among middle-aged female breast cancer survivors. PMID 42526663 — injections, cancer survivors, sadness, vaccines, breast neoplasms, neoplasms, interleukin-6, aged, drug-related side effects and adverse reactions, breast, memory | Brain Behav Immun | 2026 | 0 |
| Impact of Oncotype DX Risk Categorization and Receipt of Chemotherapy on Survival Outcomes Among Patients with Small Node-Negative HR+ Breast Cancer. PMID 42458792 — breast neoplasms, neoplasms, drug therapy, breast, chemotherapy | Oncologist | 2026 | 0 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Tersolisib (LY4064809 STX 478) With Other Anti Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) NCT07174336 — anastrozole, fulvestrant, breast neoplasms, pharmaceutical preparations, neoplasms, letrozole, neoplasm metastasis, breast, therapeutics, mutation | Phase 3 | Recruiting | 2025 |
| Abemaciclib Dose Escalation to Maintain Intensity (ADE MI) NCT06169371 — breast neoplasms, neoplasms, breast | Phase 4 | Recruiting | 2023 |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard of Care for the Treatment of Patients With Advanced or Metastatic HR HER2 Breast Cancer (VIKTORIA 1) NCT05501886 — injections, fulvestrant, aromatase, aromatase inhibitors, breast neoplasms, neoplasms, tablets, neoplasm metastasis, breast, therapeutics | Phase 3 | Active not recruiting | 2022 |
| CFI 402257 a Potent and Selective TTK Inhibitor in Solid Tumors and With Fulvestrant in Breast Cancer NCT05251714 — injections, fulvestrant, breast neoplasms, neoplasms, disease progression, breast, therapeutics, universities | Phase 1/Phase 2 | Recruiting | 2022 |
LeadR Networks
Main global connection map